Background illustration for clinical trials search

Paid Clinical Trials Murfreesboro

Discover 1,239 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for
Multiple Myeloma
Location: Nashville TN, Cincinnati OH, Indianapolis IN,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT06152575

Phase 3, Recruiting

A Study of YL242 in Subjects With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Nashville TN, Grand Rapids MI, Sarasota FL
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All

Age: 18+

Code: NCT07197827

Phase 1, Phase 2, Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Atlanta GA, Chapel Hill NC, Fairfax VA,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT07288177

Phase 2, Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for
Mantle Cell Lymphoma, B Cell Lymphoma
Location: Nashville TN, Birmingham AL, St Louis MO, Charlotte NC,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06742996

Phase 3, Recruiting

Pacritinib Effectiveness in Real-world Settings

for
Myelofibrosis (MF)
Location: Nashville TN, Columbus OH, Charleston SC, Tampa FL,
Sponsor: Swedish Orphan Biovitrum

Sex: All

Age: 18+

Code: NCT07774455

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

for
Advanced Non-small Cell Lung Cancer, EGFR Mutation,
Location: Nashville TN
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT05099172

Phase 1, Phase 2, Recruiting

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

for
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Location: Nashville TN, Columbus OH, Durham NC, Milwaukee WI,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06876649

Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

for
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Location: Nashville TN, Atlanta GA, Columbus OH, Durham NC,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06876662

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for
Breast Neoplasms
Location: Nashville TN, Lexington KY, Cincinnati OH, Charlotte NC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07060807

Phase 3, Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for
Advanced Non-Small Cell Lung Cancer,
Location: Nashville TN, Marietta GA, Louisville KY, Germantown TN,
Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT04613596

Phase 2, Phase 3, Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for
Hormone Receptor Positive HER-2 Negative Breast Cancer,
Location: Nashville TN, Birmingham AL, Atlanta GA, St Louis MO,
Sponsor: Puma Biotechnology, Inc.

Sex: All

Age: 18+

Code: NCT06369285

Phase 2, Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma, Myeloma, Myeloma Multiple
Location: Nashville TN, Atlanta GA, Charlotte NC, Durham NC,
Sponsor: K36 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05651932

Phase 1, Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

for
Chronic Lymphocytic Leukemia (CLL),
Location: Nashville TN, Chicago IL, Bethesda MD, Houston TX,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT04830137

Phase 1, Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Nashville TN, Chattanooga TN, Owensboro KY, Edgewood KY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136559

Phase 3, Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Nashville TN, Memphis TN, Cleveland OH, Pittsburgh PA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06162221

Phase 1, Phase 2, Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for
Non Small Cell Lung Cancer, Triple Negative Breast Cancer,
Location: Nashville TN, Athens GA, Fort Wayne IN, Orlando FL,
Sponsor: Compass Therapeutics

Sex: All

Age: 18+

Code: NCT06150664

Phase 1, Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumor
Location: Nashville TN, Atlanta GA, St Louis MO, Wilson NC,
Sponsor: Pliant Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06270706

Phase 1, Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Nashville TN, Birmingham AL, Atlanta GA,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06121843

Phase 1, Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for
Advanced Melanoma
Location: Nashville TN, Knoxville TN, Greenville SC, Edgewood KY,
Sponsor: Immunocore Ltd

Sex: All

Age: 18+

Code: NCT06112314

Phase 3, Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

for
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma,
Location: Nashville TN, Chattanooga TN, Birmingham AL, Newnan GA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT05006716

Phase 1, Phase 2, Recruiting